Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products - SC Read more about Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products - SC
Zai Lab Announces Participation in Investor Conferences in November 2026 - SC Read more about Zai Lab Announces Participation in Investor Conferences in November 2026 - SC
再鼎医药公布新型IL-13/IL-31Rα双特异性抗体ZL-1503首次人体研究阳性数据,显示出对特应性皮炎关键生物标志物实现快速且持续的抑制,血清半衰期延长支持更低的给药频率 Read more about 再鼎医药公布新型IL-13/IL-31Rα双特异性抗体ZL-1503首次人体研究阳性数据,显示出对特应性皮炎关键生物标志物实现快速且持续的抑制,血清半衰期延长支持更低的给药频率
Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas - SC Read more about Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas - SC
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - SC Read more about Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - SC
Zai Lab Announces $250 Million Private Placement - SC Read more about Zai Lab Announces $250 Million Private Placement - SC
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 - SC Read more about Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 - SC
再鼎医药将公布评估 ZL-1503(IL-13/IL-31Rα 双特异性抗体)用于特应性疾病的首个临床研究数据 Read more about 再鼎医药将公布评估 ZL-1503(IL-13/IL-31Rα 双特异性抗体)用于特应性疾病的首个临床研究数据
再鼎医药将公布Zocilurtatug Pelitecan(Zoci)一线治疗广泛期小细胞肺癌(ES-SCLC)的首个全球临床数据 Read more about 再鼎医药将公布Zocilurtatug Pelitecan(Zoci)一线治疗广泛期小细胞肺癌(ES-SCLC)的首个全球临床数据
再鼎医药与 argenx 宣布艾加莫德用于治疗自身免疫性肌炎的3 期 研究ALKIVIA取得阳性主要结果 Read more about 再鼎医药与 argenx 宣布艾加莫德用于治疗自身免疫性肌炎的3 期 研究ALKIVIA取得阳性主要结果